Sirius Therapeutics secures $50 million in Series B2 funding to advance its novel siRNA-based therapies targeting cardiometabolic disorders. The round includes participation from BioTrack Capital as a new investor, alongside returning backers OrbiMed, Creacion Ventures, and Hankang Capital, alongside an unnamed corporate venture firm. Proceeds will support clinical development and further innovation in RNA delivery technologies.
Odyssey Therapeutics secures **$101 million in Series C funding** to advance its precision immunomodulators and oncology medicines. The round is led by **Ascenta Capital**, with participation from investors including **OrbiMed, SR One, General Catalyst**, and others. The company focuses on next-generation therapies targeting immune system modulation for cancer treatment.
Odyssey Therapeutics secures a fully subscribed $168 million in Series B funding to advance its precision immunomodulators and oncology treatments. The company develops next-generation therapies targeting immune system modulation for cancer patients. This financing reflects strong investor confidence in its pipeline of experimental medicines.
Odyssey Therapeutics secures **$218 million in Series A funding** to advance its next-generation biotechnology innovations. The company, specializing in cutting-edge therapeutic solutions, partners with law firm **Covington** for the financing round. This capital supports research and development in its core pipeline of experimental treatments.
WuXi AppTec commits **$5 million** to **Creacion Ventures I**, a venture fund. The company expands its financial support for early-stage investments through this allocation. Details on the fund’s focus or portfolio companies are not disclosed in the announcement.
Creacion Ventures
Creacion Ventures is a life-sciences venture capital firm that directs venture investment toward companies pursuing medical innovation.